19
Aug
2016

Illumina Takeout? Ha!, Portola Stumbles, and NYT Biotech Ace Moves On

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

WuXi Feels Heat, Cerevel Hits Parkinson’s Goal & More GLP-1 Good News
Vertex Antes for Alpine, Regeneron Faces DOJ Scrutiny, & the Illumina Shakeup
A ProfoundBio Windfall, Amylyx Yanks Failed ALS Drug, & Verve’s Rough Patch
Boundless’ IPO, Merck’s Acceleron Win, & Moderna’s $750M Flu Vaccine Boost